A Quest for Survival: A Review of the Early Biomarkers of Pancreatic Cancer and the Most Effective Approaches at Present

Biomolecules, Год журнала: 2024, Номер 14(3), С. 364 - 364

Опубликована: Март 19, 2024

Pancreatic cancer (PC) is the most lethal type of cancer; it has lowest 5-year survival rate among all other types cancers. More than half PC cases are diagnosed at an advanced stage due to PC’s insidious and non-specific symptoms. Surgery remains efficacious treatment option currently available, but only 10–20% resectable upon diagnosis. As now, sole biomarker approved by United States Food Drug Administration (US-FDA) for carbohydrate antigen 19-9 (CA19-9); however, its use limited early An increasing number studies have investigated a combination biomarkers. Lately, there been considerable interest in application liquid biopsy, including utilization microRNAs (miRNAs), circulating tumor DNA (ctDNA), cells (CTCs). Screening indicated high-risk patients; on new diagnostic models combined with biomarkers detection also shown promising results terms ability these aid clinicians deciding whether start screening. This review seeks provide concise overview advancements relation existing explore novel strategies PC.

Язык: Английский

---

New Frontiers in Pancreatic Cancer Management: Current Treatment Options and the Emerging Role of Neoadjuvant Therapy

Medicina, Год журнала: 2024, Номер 60(7), С. 1070 - 1070

Опубликована: Июнь 28, 2024

Pancreatic ductal adenocarcinoma (PDAC) ranks among the 15 most prevalent cancers globally, characterized by aggressive growth and late-stage diagnosis. Advances in imaging surgical techniques have redefined classification of pancreatic PDAC into resectable, borderline locally advanced cancer. While surgery remains effective treatment, only 20% patients are eligible at diagnosis, necessitating innovative strategies to improve outcomes. Therefore, traditional treatment paradigms, primarily resection for patients, increasingly supplemented neoadjuvant therapies (NAT), which include chemotherapy, radiotherapy, or a combination both. By administering systemic therapy prior surgery, NAT aims reduce tumor size increase feasibility complete resection, thus enhancing overall survival rates potentially allowing more undergo curative surgeries. Recent advances protocols, such as FOLFIRINOX gemcitabine-nab-paclitaxel, now integral strategies, shown promising results increasing proportion effectively reducing addressing micrometastatic disease. Additionally, they offer improved response benefits compared regimes. Despite these advancements, role continues evolve, ongoing research optimize regimens, minimize adverse effects, identify patient populations that would benefit from approaches. Through detailed analysis current literature recent clinical trials, this review highlights transformative potential managing PDAC, especially with resectable stages, shift towards personalized management PDAC.

Язык: Английский

---

Personalised PET imaging in oncology: an umbrella review of meta-analyses to guide the appropriate radiopharmaceutical choice and indication

European Journal of Nuclear Medicine and Molecular Imaging, Год журнала: 2024, Номер unknown

Опубликована: Сен. 11, 2024

Язык: Английский

---

Pancreatic Adenocarcinoma: Long-Term Outcomes of Adjuvant Therapy in the ESPAC4 Phase III Trial

Journal of Clinical Oncology, Год журнала: 2024, Номер unknown

Опубликована: Дек. 5, 2024

PURPOSE The ESPAC4 trial showed that adjuvant chemotherapy with gemcitabine plus capecitabine (GemCap) produced longer overall survival (OS) than monotherapy. Subsequently, the PRODIGE24-CCTG PA.6 even for modified fluorouracil, folinic acid, irinotecan, and oxaliplatin (mFOLFIRINOX) but had more restrictive eligibility criteria. Our aim was to analyze on long-term follow-up. METHODS OS of 732 patients comparing 367 randomly assigned 365 GemCap previously reported after a median follow-up time 43.2 months (95% CI, 39.7 45.5) 458 deaths. Analysis now carried out 104 (101-108) 566 RESULTS 29.5 (27.5-32.1) all patients, 28.4 (25.2-32.0) in group 31.6 (26.5-38.0) (hazard ratio [HR], 0.83 [0.71 0.98]; P = .031). R0 given 32.2 (27.9-41.6) compared 49.9 (39.0-82.3) those (HR, 0.63 [0.47 0.84]; .002). Lymph node-negative significantly higher 5 year rates (59% [49%-71%]) (53% [42%-66%]; HR, [0.41 .04) not positive lymph nodes ( .225). advantage retained PRODIGE24 subgroup 193 (26.4%) eligible 20.7 (16.2-27.3) allocated 25.9 (22.3-30.2) ineligible 0.71 [95% 0.52 χ 2 log-rank-1df 4.31; .038). CONCLUSION is standard option mFOLFIRINOX. Exploratory evidence suggests may be particularly efficacious also patients.

Язык: Английский

---

A Systematic Review of Indications and Clinical Outcomes of Electrochemotherapy in Pancreatic Ductal Adenocarcinoma

Cancers, Год журнала: 2025, Номер 17(3), С. 408 - 408

Опубликована: Янв. 26, 2025

Background: Pancreatic ductal adenocarcinoma (PDAC) is one of the most difficult cancers to treat, with a dismal 5-year survival rate only 8–10%. This challenging prognosis highlights urgent need for innovative therapeutic approaches improve outcomes patients PDAC. Electrochemotherapy (ECT), which enhances intracellular chemotherapeutic uptake via electric pulses, has been explored resectable, borderline resectable (BR), locally advanced (LA), recurrent, and metastatic PDAC, either as complement conventional treatments or an alternative when these are not feasible effective, offering possible benefits in symptomatic palliation local tumor control. Methods: A systematic review was performed accordance PRISMA guidelines studies assessing efficacy ECT After searching Embase, PubMed/MEDLINE, Scopus, Web Science, five combined total 43 various disease stages were identified. Results: showed promise improving control, alleviating cancer-related pain, quality life. One study noted trend towards size reduction 8.3% at one-month 16.1% six-months follow-up (p = 0.211 p 0.315), although findings derived from conducted without specific comparative control groups. Severity complication mainly mild (Clavien–Dindo I-II), while severe complications occurred 2.3% patients. Median overall reported two 8 months (range 2–19) 11.5 1–74). symptom management, 60% reporting reduced pain/discomfort 40% showing enhanced life study, another pain scores decreasing 6 3 month 2 six months. Conclusions: appears be new promising safe adjunct treatment modality PDAC management across different stages, potential reduction, Further warranted validate identify who could benefit most.

Язык: Английский

---

Real-world management and outcome of patients with pancreatic adenocarcinoma. Results of the Spanish RETUD gastrointestinal registry

ESMO Real World Data and Digital Oncology, Год журнала: 2025, Номер 7, С. 100116 - 100116

Опубликована: Фев. 17, 2025

Язык: Английский

---

Examining the dietary contributions of lipids to pancreatic cancer burden (1990–2021): incidence trends and future projections

Lipids in Health and Disease, Год журнала: 2025, Номер 24(1)

Опубликована: Фев. 21, 2025

Pancreatic cancer (PC) ranks sixth globally among deaths, imposing a significant burden on healthcare systems worldwide. Although diet is known to be major risk factor, well-established factor for PC, the precise dietary components linked disease remain inconclusive, with studies showing varying results across different populations and regions. This study addresses this gap through comprehensive analysis of PC incidence trends from 1990 2021, specific focus associations age, patterns, socio-demographic determinants. The data utilized in were obtained 2021 Global Burden Disease (GBD) database, updated May 16, 2024. Unlike traditional single-variable correlation analyses, Bayesian generalized linear model was applied assess association between food intake during period 1990–2021. To account variations related year region, these variables incorporated as covariates model, allowing more nuanced background factors. Finally, "BAPC" package employed project age-standardized rates 2051. global increased 3.90 per 100,000 people (95% CI: 3.69, 4.08) 6.44 5.86, 6.93) 2021. revealed nuts, omega-3 fatty acids, polyunsaturated acids (PUFA), trans fats, sodium, calcium. In typical countries, higher nuts PUFA associated reduced while fats positively correlated incidence. Age-Period-Cohort (BAPC) prediction indicates that will show downward trend after From exhibited rapid upward trend, suggesting an increasing burden. findings suggest lipid significantly at level. finding underscores importance fat composition, particularly context pancreatic prevention, individuals should pay attention types sources their diets mitigate risk.

Язык: Английский

---

Trends in the Global Incidence of Pancreatic Cancer and a Brief Review of its Histologic and Molecular Subtypes

Journal of Gastrointestinal Cancer, Год журнала: 2025, Номер 56(1)

Опубликована: Фев. 24, 2025

Язык: Английский

---

State of the Art of Immune Checkpoint Inhibitors in Unresectable Pancreatic Cancer: A Comprehensive Systematic Review

International Journal of Molecular Sciences, Год журнала: 2025, Номер 26(6), С. 2620 - 2620

Опубликована: Март 14, 2025

Immune checkpoint inhibitors (ICIs) have transformed the therapeutic landscape for several malignancies, but their efficacy in unresectable pancreatic adenocarcinoma remains uncertain. This systematic review aimed to evaluate effectiveness and safety of ICIs this context, focusing on overall survival (OS), progression-free (PFS), objective response rate (ORR), disease control (DCR), toxicity. A comprehensive search MEDLINE, EMBASE, CENTRAL, Scopus identified 34 eligible studies, including randomized controlled trials observational cohorts. Quantitative synthesis involved 21 studies comprising 937 patients, with additional qualitative analyses biomarker-driven subgroups early-phase trials. The median OS across was 8.65 months, while PFS 2.55 months. ORR DCR were 16.2% 50.3%, respectively, grade ≥3 treatment-related adverse events occurring 22% patients. Promising outcomes observed MSI-H/dMMR populations, although these represented only 1–2% cases. Combination strategies chemotherapy demonstrated synergistic potential lacked definitive evidence due heterogeneity absence phase III showed a manageable toxicity profile, highlighting feasibility selected Future research should focus overcoming tumor microenvironment barriers identifying biomarkers optimize responsiveness expand applicability cancer.

Язык: Английский

---

The growing field of liquid biopsy and its Snowball effect on reshaping cancer management

The Journal of Liquid Biopsy, Год журнала: 2025, Номер unknown, С. 100293 - 100293

Опубликована: Март 1, 2025

Liquid biopsy (LB) has emerged as a transformative tool in oncology, providing minimally invasive approach for tumor detection, molecular characterization, and real-time treatment monitoring. By analyzing circulating DNA (ctDNA), cells (CTCs), extracellular vesicles (EVs), microRNA (miRNA), LB enables comprehensive profiling without the need traditional tissue biopsies. Over past decade, research this field expanded exponentially, leading to integration of into clinical practice specific cancer types, including lung breast cancer. In 2024, Journal Biopsy (JLB) published innovative studies exploring latest advancements technologies, biomarkers, their applications minimal residual disease (MRD) monitoring, therapy response assessment. This review synthesizes recent findings on role monitoring across different with particular focus newly context within translational research. Additionally, it highlights emerging techniques such fragmentomics, artificial intelligence, multiomics, paving way more precise, personalized decisions. Despite these advancements, challenges remain standardizing methodologies, optimizing validation, integrating routine oncological workflows. mini-review evolving landscape its potential revolutionize diagnosis, therapeutic decision-making, ushering new era precision oncology.

Язык: Английский

---